Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
AssigneeBiovec, LLC
InventorsLakshman R. Sehgal, Jonathan Wong
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
Claims14
A method for treating a vascular disease in a mammal, said method comprising the steps of:
- administering intravenously an effective amount of a gutless adenoviral vector comprising a polynucleotide encoding a functional thrombomodulin protein having the amino acid sequence of SEQ ID NO:
- 2 and a regulatory element operably linked to said polynucleotide,
- wherein said gutless adenoviral vector comprises the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses said functional thrombomodulin protein in said mammal, and wherein said vascular disease is selected from the group consisting of atherosclerotic cardiovascular disease, myocardial infraction, fibrinolysis in hemophilic plasma, and end stage renal failure.
A method for treating a vascular disease in a mammal, said method comprising the steps of:
- administering intravenously an effective amount of a gutless adenoviral vector comprising a polynucleotide encoding a functional thrombomodulin protein and a regulatory element operably linked to said polynucleotide,
- wherein said gutless adenoviral vector further comprises the nucleotide sequence of SEQ ID NO:13 and SEQ ID NO:15 and expresses said thrombomodulin in said mammal, and wherein said vascular disease is selected from the group consisting of atherosclerotic cardiovascular disease, myocardial infraction, fibrinolysis in hemophilic plasma, and end stage renal failure.
Dependencies are inferred from the claim text.